445430-58-0 Usage
Uses
Used in Cancer Research:
IKK Inhibitor III, BMS-345541 is used as a research tool for studying the role of IKK and NF-kB in cancer development and progression. It helps in understanding the molecular mechanisms underlying tumor growth and identifying potential therapeutic targets.
Used in Neuroscience Research:
IKK Inhibitor III, BMS-345541 is used as a research compound in neuroscience to investigate the involvement of IKK and NF-kB in neurodegenerative diseases and neuroinflammation. It aids in exploring the potential of IKK inhibition as a therapeutic strategy for neurological disorders.
Used in Immunology Research:
IKK Inhibitor III, BMS-345541 is used as an immunological agent to study the regulation of immune responses and inflammation. It is instrumental in examining the effects of IKK inhibition on immune cell activation and function, as well as the potential for modulating immune-mediated diseases.
Used in Drug Development:
IKK Inhibitor III, BMS-345541 is used as a lead compound in the development of new drugs targeting IKK and NF-kB pathways. It serves as a starting point for designing and optimizing therapeutic agents that could potentially treat various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 445430-58-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,5,4,3 and 0 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 445430-58:
(8*4)+(7*4)+(6*5)+(5*4)+(4*3)+(3*0)+(2*5)+(1*8)=140
140 % 10 = 0
So 445430-58-0 is a valid CAS Registry Number.
445430-58-0Relevant academic research and scientific papers
Imidazoquinoxaline compound for the treatment of melanoma
-
Page/Page column 5, (2008/06/13)
The present invention concerns a (4(2′-aminoethyl)amino-1,8-dimethylimididazo(1,2-a)quinoxaline)-4,5-dihydro-1,8-dimethylimidazo(1,2-a)quinoxalin-4-one-2-carboxylic acid (BMS-345541) or an analog thereof for the treatment of melanoma cancer. This compound inhibits NFκB activity and expression, and induces apoptosis in melanoma cancer cells. The present invention also provides a method for assaying for the inhibition of melanoma cancer cell growth.
